CULLINAN THERAPEUTICS, INC. Research and Development Expense
CULLINAN THERAPEUTICS, INC. (CGEM) reported Research and Development Expense of $44.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $44.44M, a 27.19% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $42.12M, a 1.60% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $42.95M, a 6.06% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $41.97M, a 18.20% increase year-over-year.
- CULLINAN THERAPEUTICS, INC. research and development expense for fiscal 2025 was $187.40M, a 31.14% increase from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. research and development expense for fiscal 2024 was $142.90M, a 3.55% decline from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. research and development expense for fiscal 2023 was $148.16M, a 61.13% increase from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. research and development expense for fiscal 2022 was $91.95M, a 59.21% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.44M 10-Q · filed 2026-08-06 | $86.56M 10-Q · filed 2026-08-06 | $129.50M derived: sum of 3 quarters · filed 2026-08-06 | $171.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $42.12M 10-Q · filed 2026-05-07 | $85.07M derived: sum of 2 quarters · filed 2026-05-07 | $127.04M derived: sum of 3 quarters · filed 2026-05-07 | $188.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $42.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $84.91M derived: sum of 2 quarters · filed 2026-03-10 | $145.94M derived: sum of 3 quarters · filed 2026-08-06 | $187.40M 10-K · filed 2026-03-10 |
| 2025-09-30 | $41.97M 10-Q · filed 2025-11-06 | $103.00M derived: sum of 2 quarters · filed 2026-08-06 | $144.46M 10-Q · filed 2025-11-06 | $184.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $61.03M 10-Q · filed 2026-08-06 | $102.49M 10-Q · filed 2026-08-06 | $142.98M derived: sum of 3 quarters · filed 2026-08-06 | $178.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $41.46M 10-Q · filed 2026-05-07 | $81.95M derived: sum of 2 quarters · filed 2026-05-07 | $117.46M derived: sum of 3 quarters · filed 2026-05-07 | $153.72M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $40.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $76.00M derived: sum of 2 quarters · filed 2026-03-10 | $112.26M derived: sum of 3 quarters · filed 2026-03-10 | $142.90M 10-K · filed 2026-03-10 |
| 2024-09-30 | $35.51M 10-Q · filed 2025-11-06 | $71.77M derived: sum of 2 quarters · filed 2025-11-06 | $102.41M 10-Q · filed 2025-11-06 | $137.26M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $36.26M 10-Q · filed 2025-08-07 | $66.91M 10-Q · filed 2025-08-07 | $101.75M derived: sum of 3 quarters · filed 2025-08-07 | $135.57M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $30.65M 10-Q · filed 2025-05-08 | $65.49M derived: sum of 2 quarters · filed 2025-05-08 | $99.31M derived: sum of 3 quarters · filed 2025-05-08 | $126.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $34.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $68.67M derived: sum of 2 quarters · filed 2025-02-27 | $96.06M derived: sum of 3 quarters · filed 2025-02-27 | $148.16M 10-K · filed 2025-02-27 |
| 2023-09-30 | $33.82M 10-Q · filed 2024-11-07 | $61.21M derived: sum of 2 quarters · filed 2024-11-07 | $113.31M 10-Q · filed 2024-11-07 | $134.63M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $27.39M 10-Q · filed 2024-08-08 | $79.49M 10-Q · filed 2024-08-08 | $100.81M derived: sum of 3 quarters · filed 2024-08-08 | $120.49M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $52.10M 10-Q · filed 2024-05-15 | $73.42M derived: sum of 2 quarters · filed 2024-05-15 | $93.10M derived: sum of 3 quarters · filed 2024-05-15 | $119.51M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $21.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $41.00M derived: sum of 2 quarters · filed 2024-03-14 | $67.41M derived: sum of 3 quarters · filed 2024-03-14 | $91.95M 10-K · filed 2024-03-14 |
| 2022-09-30 | $19.68M 10-Q · filed 2023-11-08 | $46.09M derived: sum of 2 quarters · filed 2023-11-08 | $70.63M 10-Q · filed 2023-11-08 | $91.50M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $26.41M 10-Q · filed 2023-08-10 | $50.95M 10-Q · filed 2023-08-10 | $71.83M derived: sum of 3 quarters · filed 2023-08-10 | $84.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $24.54M 10-Q · filed 2023-05-11 | $45.41M derived: sum of 2 quarters · filed 2023-05-11 | $58.09M derived: sum of 3 quarters · filed 2023-05-11 | $69.87M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $20.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $33.56M derived: sum of 2 quarters · filed 2023-03-09 | $45.34M derived: sum of 3 quarters · filed 2023-03-09 | $57.75M 10-K · filed 2023-03-09 |
| 2021-09-30 | $12.68M 10-Q · filed 2022-11-14 | $24.46M derived: sum of 2 quarters · filed 2022-11-14 | $36.87M 10-Q · filed 2022-11-14 | $53.50M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $11.78M 10-Q · filed 2022-08-10 | $24.19M 10-Q · filed 2022-08-10 | $40.82M derived: sum of 3 quarters · filed 2022-08-10 | $50.73M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $12.41M 10-Q · filed 2022-05-16 | $29.04M derived: sum of 2 quarters · filed 2022-05-16 | $38.96M derived: sum of 3 quarters · filed 2022-05-16 | $51.45M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $16.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $26.54M derived: sum of 2 quarters · filed 2022-03-17 | $39.04M derived: sum of 3 quarters · filed 2022-03-17 | $43.21M 10-K · filed 2022-03-17 |
| 2020-09-30 | $9.91M 10-Q · filed 2021-11-09 | $22.41M derived: sum of 2 quarters · filed 2021-11-09 | $26.58M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $12.50M 10-Q · filed 2021-08-10 | $16.67M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $4.17M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |